13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
95 檔
15.6%
As reported in its official Q2 2025 Form 13F filing, Soleus Capital Management, L.P.'s tracked investment portfolio stood at $2.9B with 95 total positions.
In Q2 2025, Soleus Capital Management, L.P. displayed an active expansion posture, initiating 15 new positions and adding to 14 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 8.40% | -0.03% | +108.93% | |
| 2 | NVCR | NovoCure Limited | Stock-Healthcare | 8.14% | +0.55% | +25.05% | |
| 3 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 5.35% | +0.12% | -21.17% | |
| 4 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 4.12% | — | -46.43% | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.99% | -0.29% | +35.01% | |
| 6 | BBNX | Beta Bionics Inc | Stock-Other | 3.68% | +0.60% | +12.51% | |
| 7 | GRFS | Grifols Sa-adr | Stock-Other | 3.45% | — | -18.80% | |
| 8 | STAA | Staar Surgical Co | Stock-Other | 3.32% | -0.02% | EXIT | |
| 9 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.28% | -0.75% | -16.40% | |
| 10 | ORGO | Organogenesis Holdings Inc | Stock-Other | 2.99% | -0.12% | -1.08% | |
| 11 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.69% | -2.26% | -15.18% | |
| 12 | CELC | Celcuity Inc | Stock-Other | 2.66% | +0.20% | +17.00% | |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.31% | -1.42% | — | |
| 14 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.02% | — | — | |
| 15 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.98% | +0.52% | — | |
| 16 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.83% | +0.63% | — | |
| 17 | ELV | Elevance Health Inc | Stock-Healthcare | 1.80% | — | — | |
| 18 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.78% | +1.15% | NEW | |
| 19 | NPCE | Neuropace Inc | Stock-Other | 1.71% | +0.03% | -11.32% | |
| 20 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.57% | +0.54% | +48.15% | |
| 21 | SU6 | Surmodics Inc | Stock-Other | 1.55% | — | — | |
| 22 | GERN | Geron CORP | Stock-Other | 1.51% | -0.61% | +572.50% | |
| 23 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.49% | — | — | |
| 24 | EOLS | Evolus Inc | Stock-Other | 1.29% | -0.17% | +96.36% | |
| 25 | HUM | Humana Inc | Stock-Healthcare | 1.29% | — | — | |
| 26 | VCYT | Veracyte Inc | Stock-Other | 1.28% | -0.37% | — | |
| 27 | IART | Integra Lifesciences Holding | Stock-Other | 1.13% | — | +29.44% | |
| 28 | AXGN | Axogen Inc | Stock-Other | 1.05% | -0.82% | +0.92% | |
| 29 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.01% | -1.20% | — | |
| 30 | ASND | Ascendis Pharma A/S | Stock-Other | 0.97% | — | +50.98% | |
| 31 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.94% | +1.77% | +179.49% | |
| 32 | TWST | Twist Bioscience CORP | Stock-Other | 0.86% | -1.99% | — | |
| 33 | PHVS | Pharvaris N.V. | Stock-Other | 0.85% | +0.07% | -10.03% | |
| 34 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.82% | +0.02% | — | |
| 35 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.82% | +2.48% | -41.79% | |
| 36 | FOCL | Edap Tms SA -adr | Stock-Other | 0.80% | +0.20% | — | |
| 37 | TQ80 | Theratechnologies Inc | Stock-Other | 0.75% | — | — | |
| 38 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.68% | -0.40% | +33.74% | |
| 39 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.66% | +0.13% | — | |
| 40 | ENOV | Enovis CORP | Stock-Other | 0.65% | — | — | |
| 41 | NUVL | Nuvalent Inc-a | Stock-Other | 0.63% | — | -41.69% | |
| 42 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.60% | — | — | |
| 43 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.55% | -0.01% | EXIT | |
| 44 | ACLXGBX | Arcellx Inc | Stock-Other | 0.54% | — | -19.60% | |
| 45 | JBIO | Jade Biosciences Inc | Stock-Other | 0.53% | +0.74% | — | |
| 46 | INSM | Insmed Inc | Stock-Healthcare | 0.48% | +0.26% | -73.47% | |
| 47 | ANAB | Anaptysbio Inc | Stock-Other | 0.47% | -0.01% | EXIT | |
| 48 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.47% | -0.48% | -45.75% | |
| 49 | SION | Sionna Therapeutics Inc | Stock-Other | 0.43% | -0.21% | +56.67% | |
| 50 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.43% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | +2.7% | +108.93% | Add |
| 2 | ALNY | Alnylam Pharmaceuticals Inc | +2.3% | NEW | New buy |
| 3 | URGN | UroGen Pharma Ltd. | +2% | NEW | New buy |
| 4 | ELV | Elevance Health Inc | +1.8% | NEW | New buy |
| 5 | UNH | Unitedhealth Group Inc | +1.8% | NEW | New buy |
| 6 | CDTX | Cidara Therapeutics Inc | +1.5% | NEW | New buy |
| 7 | HUM | Humana Inc | +1.3% | NEW | New buy |
| 8 | VCYT | Veracyte Inc | +1.3% | NEW | New buy |
| 9 | GERN | Geron CORP | +1.2% | +572.50% | Add |
| 10 | NVCR | NovoCure Limited | +1.1% | +25.05% | Add |
| 11 | MIRM | Mirum Pharmaceuticals Inc | +1% | NEW | New buy |
| 12 | TWST | Twist Bioscience CORP | +0.9% | NEW | New buy |
| 13 | CELC | Celcuity Inc | +0.8% | +17.00% | Add |
| 14 | BBNX | Beta Bionics Inc | +0.7% | +12.51% | Add |
| 15 | ENOV | Enovis CORP | +0.7% | NEW | New buy |
| 16 | ✓ | Establishment Labs Holdings In | +0.6% | NEW | New buy |
| 17 | UTHR | United Therapeutics CORP | +0.5% | +35.01% | Add |
| 18 | JBIO | Jade Biosciences Inc | +0.5% | NEW | New buy |
| 19 | INSP | Inspire Medical Systems Inc | +0.5% | +179.49% | Add |
| 20 | ✓ | Crescent Biopharma Inc. | +0.4% | NEW | New buy |
| 21 | 430 | Terns Pharmaceuticals Inc | +0.4% | — | Unchanged |
| 22 | EOLS | Evolus Inc | +0.4% | +96.36% | Add |
| 23 | IDYA | Ideaya Biosciences Inc | +0.4% | NEW | New buy |
| 24 | ARGX | Argenx Se - Adr | +0.3% | +48.15% | Add |
| 25 | ASND | Ascendis Pharma A/S | +0.3% | +50.98% | Add |
| 26 | ANAB | Anaptysbio Inc | +0.3% | +214.58% | Add |
| 27 | QDEL | Quidelortho CORP | +0.3% | NEW | New buy |
| 28 | STAA | Staar Surgical Co | +0.1% | +16.46% | Add |
| 29 | SRRK | Scholar Rock Holding CORP | -0.4% | -56.14% | Trim |
| 30 | TNDM | Tandem Diabetes Care Inc | -0.4% | -59.68% | Trim |
| 31 | NUVL | Nuvalent Inc-a | -0.5% | -41.69% | Trim |
| 32 | TEVA | Teva Pharmaceutical-sp Adr | -0.5% | EXIT | Sold out |
| 33 | OFIX | Orthofix Medical Inc | -0.5% | -56.61% | Trim |
| 34 | IART | Integra Lifesciences Holding | -0.6% | +29.44% | Add |
| 35 | PTGX | Protagonist Therapeutics Inc | -0.6% | EXIT | Sold out |
| 36 | NPCE | Neuropace Inc | -0.6% | -11.32% | Trim |
| 37 | RIGL | Rigel Pharmaceuticals Inc | -0.6% | -41.79% | Trim |
| 38 | SLNOEUR | Soleno Therapeutics Inc | -0.7% | -93.33% | Trim |
| 39 | ANIP | Ani Pharmaceuticals Inc | -0.9% | -77.42% | Trim |
| 40 | AXGN | Axogen Inc | -0.9% | +0.92% | Add |
| 41 | ORGO | Organogenesis Holdings Inc | -0.9% | -1.08% | Trim |
| 42 | SNY | Sanofi-adr | -0.9% | EXIT | Sold out |
| 43 | ✓ | Merus N V | -1% | -89.63% | Trim |
| 44 | INSM | Insmed Inc | -1% | -73.47% | Trim |
| 45 | HO1 | Hologic Inc | -1.3% | EXIT | Sold out |
| 46 | MDGL | Madrigal Pharmaceuticals Inc | -1.5% | -88.15% | Trim |
| 47 | IOVA | Iovance Biotherapeutics Inc | -1.5% | -58.10% | Trim |
| 48 | BMRN | Biomarin Pharmaceutical Inc | -2.2% | -16.40% | Trim |
| 49 | TGTX | Tg Therapeutics Inc | -2.7% | -21.17% | Trim |
| 50 | XBI | Ss Spdr S&p Biotech ETF | -4.1% | -46.43% | Trim |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 95 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KRYS, NVCR, TGTX) accounted for 15.6% of total reported equity market value during Q2 2025.
Top New Position Initiated
ALNY
市值: $34.8M
Top Position Liquidated / Trimmed
HO1
前期市值: $18.7M
During Q2 2025, Soleus Capital Management, L.P.'s top holdings by market value included KRYS (8.4%)、NVCR (8.1%)、TGTX (5.3%). The largest single position, KRYS, represented 8.4% of total portfolio value.
In Q2 2025, Soleus Capital Management, L.P. made 49 total portfolio adjustments, initiating 15 new buys, adding to 14 positions, trimming 16 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.